Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
18014 participants
OBSERVATIONAL
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Symbicort in Chronic Obstructive Pulmonary Disease
NCT00611520
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
NCT00206167
Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00837629
Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients
NCT01921127
Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)
NCT01253473
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients with COPD treated with budesonide/formoterol
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Germany
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kai Richter, MD
Role: STUDY_CHAIR
Medical Department AstraZeneca Germany
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
budesonide /formoterol
Identifier Type: -
Identifier Source: secondary_id
German PMS trial no.8
Identifier Type: -
Identifier Source: secondary_id
1312006001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.